Innovative Drug Clinical Development & Pipeline Licensing Advisory
With deep roots in China's biopharmaceutical ecosystem, we deliver end-to-end transaction advisory services to pharmaceutical companies, biotechs and investment firms — spanning clinical development, pipeline asset valuation, target sourcing, negotiation support, and corporate roadshow & partnership matchmaking
Company Introduction
Founded in 2024 and headquartered in Chengdu, InCreForce MKT specializes in innovative drug pipeline licensing and enterprise marketing services within the biopharmaceutical industry. We provide pharmaceutical companies, biotechs, investment institutions and CXOs with innovative drug pipeline transfer services (clinical development assessment and protocol design, target client sourcing and matchmaking) as well as enterprise marketing services (short-video marketing and conference & exhibition services), helping companies complete the entire journey from exposure to deal closure faster.
Chinese pharma & biotech assets
Industry decision-makers
Industry professional network
Focused on Innovative Drug Pipeline Transactions
Tailored two-way cross-border solutions underpinned by rigorous pre-transaction research
Out-Licensing
License-out
Full-service out-licensing support for domestic innovative biopharma companies
- Pipeline asset valuation, value proposition refinement and strategic deal packaging
- Targeted identification, tiered screening and prioritization of potential global licensees
- International project roadshow organization and curated business matchmaking
- Deal structuring, financial modeling and commercial negotiation support
- End-to-end support from due diligence assistance through contract execution to deal close
Biotech Roadshow & Marketing Services
Roadshow & Marketing
Closed-loop brand communication, project exposure and lead generation for Biotech & CXO companies
- End-to-end conference, forum and roadshow planning; full-scope on-site filming & execution
- Targeted outreach to engage qualified clients, industry investors and subject-matter experts
- Full-service corporate digital account management; corporate & business promotional video production
- Build value-accruing professional content assets to spark proactive industry inquiries
Pre-Transaction Research & Assessment
Pre-Transaction Research
Professional research and assessment support for cross-border transaction decision-making
- Market entry research and feasibility analysis for overseas pharma and CXO firms entering China
- Targeted sourcing and preliminary assessment of pipeline assets within specific therapeutic areas
- Analysis of sector deal landscape, precedent transactions and prevailing partnership models
Innovative Drug Clinical Development Consulting Services
Clinical Development Consulting
Tailored medical consulting for biotech companies, spanning the full lifecycle of innovative drug clinical development
- Led by two veteran Clinical Director-level medical experts with end-to-end novel drug development track records, we deliver tailored medical consulting services in clinical development for biotech companies.
- Our scope covers target value assessment, Therapeutic Product Profile (TPP) positioning, indication portfolio strategy, and full-cycle development pathway design to define your optimal R&D roadmap.
- We provide full-spectrum medical support across clinical protocol design, benefit-risk governance, medical monitoring, and regulatory submissions.
- Drawing on frontline hands-on expertise, we mitigate development risks, optimize program timelines, and drive steady value appreciation of your innovative pipeline assets.
Four Specialized Service Delivery Models
Market Research Service
China Market
Focused exclusively on China's innovative drug and biopharmaceutical market, we deliver customized in-depth research aligned with pre-decision needs for cross-border transactions. Coverage spans core dimensions including competitive landscape across specific therapeutic areas, drug regulatory policies, reimbursement and commercialization environment, precedent transaction benchmarking and market size estimation.
Target Sourcing & Screening
Asset Identification
Aligned with clients' strategic priorities and transaction objectives, we conduct targeted identification of innovative drug pipeline assets across China. We perform comprehensive multi-dimensional evaluation and tiered screening across scientific merit, clinical progress, patent portfolio, commercial potential and R&D team credentials, delivering a prioritized shortlist of highly matched targets.
Transaction Support Service
Deal Execution
We provide end-to-end deal execution support for in-licensing, out-licensing and domestic pipeline collaborations, including partner introduction and liaison, commercial negotiation coordination, deal structuring, risk-adjusted valuation, due diligence assistance, contract term negotiation and post-deal implementation follow-up.
Biotech Roadshow & Marketing Services
Marketing Execution
Provides end-to-end marketing support in brand communication, project exposure and lead generation for Biotech & CXO companies, including end-to-end planning for conferences, forums and roadshows, on-site filming & execution, targeted outreach to engage qualified industry participants, full-service corporate digital account management, production of corporate & business promotional videos, and development of value-accruing professional content assets to spark proactive industry inquiries.
Leadership Team
Dr. Stem Hung
Head of Transaction Advisory
PhD in Pharmacy, University of Brighton (UK); Bachelor of Pharmacy, Taipei Medical University. With over 20 years of business development experience in the pharmaceutical industry, he specializes in innovative drugs, oncology, immunology, autoimmunity, cell therapy and AI-driven drug discovery. Previously held senior roles at OBI Pharma, AbGenomics, CSPC Pharmaceutical Group, Porton Pharma Solutions and Changsen Pharmaceutical.
Leslie LAI, MBA
General Manager & Head of Operations
Master's degree in Pharmacy, China Pharmaceutical University; MBA, Sichuan University. With 13 years of experience in R&D, business development and marketing operations in the biopharmaceutical sector, he previously served at Chengdu Leadgene, Pharma Circle and other industry platforms. Co-founder of major industry events including the China Pharmaceutical Industry Expo and the Improved New Drug Development Forum.
Sylvia JIANG
Head of Events & Roadshows
Graduated from Chengdu University with a major in Convention and Exhibition Management. She leads the company's event operations and project roadshow organization, and has planned and executed dozens of online and offline biopharma R&D conferences and events — including the Improved New Drug Trends & Cooperation Conference, Cell Therapy Development Conference, National Pharmaceutical Achievement Transformation Conference, and Clinical Development Trends Conference — with attendances ranging from 100 to 1,200 participants. She brings extensive industry resources and end-to-end event delivery expertise.
Dr. Guo
Head of Clinical Development Consulting
Dr. Guo brings extensive experience in immuno-oncology drug development. She obtained her PhD in Pharmacology from Peking University Health Science Center and completed postdoctoral research at the National Institutes of Health (NIH), focusing on tumor immunotherapy and new drug R&D. She previously led clinical development strategy for immuno-oncology pipelines, including clinical trial design, biomarker exploration and drug safety evaluation, and was deeply involved in the development of core assets such as envafolimab (KN035), the world's first subcutaneously administered PD-L1 inhibitor, which strongly supported its successful marketing approval. She has shared cutting-edge R&D insights at domestic and international precision oncology conferences to foster industry exchange. Her therapeutic areas of expertise include oncology, rare diseases, autoimmune disorders and infectious diseases, with work spanning ADCs, antibodies, small molecules and peptides. She independently develops high-level strategies such as asset prioritization, CDP, TPP and DAS, as well as indication and portfolio optimization. She has hands-on experience across Phase 1–3 and NDA stages, with solid command of key priorities, challenges and critical milestones in clinical protocol design and execution.
Deeply Embedded in China's Biopharmaceutical Ecosystem
Domestic Pharma & Biotech Network
We maintain a database of thousands of pharmaceutical companies, innovative biotechs and industry investment firms across China's key pharmaceutical clusters, with comprehensive visibility into pipeline portfolios, R&D progress, asset divestiture plans and partnership intentions. Coverage spans all major Chinese innovation hubs including the Yangtze River Delta, Beijing-Tianjin-Hebei region, Guangdong-Hong Kong-Macao Greater Bay Area, and Chengdu-Chongqing economic zone.
Local Expert Think Tank
A network of 500+ senior local specialists across key therapeutic and functional areas, covering the full value chain of drug R&D, clinical research, regulatory affairs, CMC, health policy and commercialization. All experts bring 15+ years of hands-on industry experience in China.
Industrial Ecosystem Partner Network
Long-term, in-depth partnerships with leading Chinese pharmaceutical industrial parks and industry associations. We also collaborate with top-tier domestic CROs/CDMOs, law firms and financial advisory institutions to deliver integrated end-to-end transaction support.
Cross-Border Integration Capabilities
Our dedicated cross-border transaction team and established international communication channels enable seamless alignment between overseas client requirements and Chinese local resources. We bring proven experience in licensing transactions between Chinese and global enterprises, with deep fluency in cross-border deal protocols and business cultures on both sides.
Selected Engagements
Successfully advanced an innovative lung cancer drug into the Malaysian and Singaporean markets
Supported the successful in-licensing of an innovative European GERD drug by a top-10 Chinese pharmaceutical company by national industry ranking
Facilitated a licensing collaboration agreement with Ildong Pharmaceutical (South Korea)
Completed the out-licensing of the PI3K inhibitor Duvelisib in the Taiwan region
Established partnership evaluation frameworks and executed Confidential Disclosure Agreements (CDAs) with multinational pharma companies including Pfizer, Galderma, Italfarmaco and Johnson & Johnson
Brokered six innovative drug R&D technical collaborations between a Chengdu-based biotech and a top-100 Chinese pharmaceutical enterprise
Contact Us
+86 135 5029 1524
leslie_denovo@sina.com
Tower A, Building 1, No. 1480 North Tianfu Avenue, High-Tech Zone, Chengdu, Sichuan Province, P.R. China
www.increforcemkt.cn